

Time to move forward: Challenges and Research Opportunities for Lung Cancer Screening and Early Detection in Europe

1 – 2 July 2021

Lisbon, Portugal

Thursday, 01 July 2021

08.30 – 08.45 Registration

08.45 – 09.00 Introduction – Jan van Meerbeeck, BE and Annemiek Snoeckx, BE

Session 1: Update on lung cancer screening: did we make any further progress?

09.00 – 09.20 Two years after NELSON: Are there data on relevant subgroup analyses or secondary endpoints? – Harry De Koning, NL

09.20 – 09.35 Presentation of ESTI initiative (Lung Cancer Screening Certification Project) – Annemiek Snoeckx, BE

09.35 – 10.00 Discussion

10.00 – 10.30 *Coffee break*

10.30 – 11.30 Break-out session I

1 per country/region: What is currently ongoing in Europe?

- Screening initiatives after the ERS research seminar 2018: an update on current trials and initiatives in different countries
 - Croatian initiative
 - UK initiative – vrouw ERS speaker
 - Italian initiative
 - German initiative
 - French initiative
 - Norwegian initiative
- How will smoking cessation be integrated into lung cancer screening in your lung cancer screening program?

11.30 – 12.00 Report to the plenary session and discussion

12.00 – 13.00 *Lunch break*

Session 2: The time to implement is now

13.00 – 13.20 Making research findings more powerful for clinical use – Sabina De Geest, CH

13.20 – 13.40 Role of the GP in participants accrual – Speaker TBC

13.40 – 14.00 Psychological impacts of lung cancer screening – Speaker TBC

14.00 – 14.30 Discussion

14.30 – 16.30 Break out session 2: presentation of research projects in Europe

- **Group 1:** The quest for biomarkers for early lung cancer
- **Group 2:** ERS-task force on handling of screen detected nodules

16.30 – 17.00 *Coffee break*

Session 3: The world does not stand still: evolution in imaging and treatment

17.00 – 17.20 Is ultra-low-dose ready for practice? – Mario Silva, IT

17.20 – 17.40 Research opportunities in nodule handling: robotic surgery and beyond – Speaker TBC

17.40 – 18.00 Artificial Intelligence in lung cancer screening – Speaker TBC

18.00 – 18.30 Discussion

Friday, 02 July 2021

Session 4: Early detection biomarkers: ready for implementation in screening?

09.00 – 09.20 Genomic screening: myths, promises and achievements – Joanna Chorostowska-Wynimko, PL

09.20 – 09.40 Biomarker performance and pathways to clinical utility – Luis M. Montuenga, ES

09.40 – 10.00 VOC's for lung cancer screening: where are we now? – Speaker TBC

10.00 – 10.30 Discussion

10.30 – 11.00 *Coffee break*

11.00 – 12.00 Report from break out session II

- Group 2 + discussion 20'
- Group 3 + discussion 20'

Session 5: Taking research forward in the ERS

12.00 – 12.20 What is the optimal design for trials incorporating biomarkers and CT-scan screening
– Pierre Massion, USA

12.20 – 12.40 Agenda for an ERS clinical research collaboration – Jan van Meerbeeck, BE

12.40 – 13.00 Remarks, wrap up and action points

13.00 – 14.00 Lunch

Meeting of the Task Force writing committee